UNSPSC 51202301: Afelimomab

This classification denotes an immunosuppressant, a biological preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SC756X51V. As of Q4 2014, AFELIMOMAB remains US FDA's Preferred Term for this commodity. Most nations, for tariff and trade purposes, schedule afelimomab under HS 30021000 and SITC 54163 (For the most current information on WCO designations on afelimomab and salts thereof, please see Committee proceedings HSC/18, 40.600 Ann. D, par. 6, 1996).

UNSPSC 51202301 Afelimomab is a Commodity code that nominally designates a specific monoclonal antibody therapeutic, yet recent state and local procurement activity under this code shows virtually no alignment with the pharmaceutical compound itself. Instead, the code appears in solicitations for naloxone (opioid overdose reversal), safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products — a mismatch suggesting either broad category misapplication or code reuse across disparate pharmaceutical procurement activities. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government facilities across multiple states including Oregon). The scope spans emergency-response pharmaceuticals, pharmacy benefit management restructuring, and bulk generic and OTC product supply contracts with established wholesaler networks.

The most recent activity appears in Florida, Texas, and Minnesota with interstate reach. Seminole County posted an Invitation for Bid (IFB 60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, response deadline July 26, 2023. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) in April 2026 to explore direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code shows limited recent relevant activity; vendors evaluating pursuit should treat the Seminole County naloxone procurement and MMCAP generic pharmaceutical framework as outliers and verify code accuracy before resource allocation.